Denali Therapeutics Inc. Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period
New shares the company issued (share-based compensation, option exercises, employee stock purchase plans, new issues, acquisitions), as filed in its 10-Q and 10-K XBRL statement of shareholders' equity. This is the dilution side; Issuer Repurchases is the other side.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-06-30 was 456.15K shares.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2026-03-31 was 536.72K shares, a 371.67% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-12-31 was 73.17K shares, a 67.36% decline year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for the quarter ending 2025-09-30 was 586.91K shares, a 101.56% increase year-over-year.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2025 was 773.88K shares, a 20.10% decline from fiscal 2024.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2024 was 968.59K shares, a 5.71% increase from fiscal 2023.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2023 was 916.24K shares, a 27.10% increase from fiscal 2022.
- Denali Therapeutics Inc. share-based compensation arrangement by share-based payment award, options, exercises in period for fiscal 2022 was 720.90K shares, a 29.40% decline from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Exercises in Period 12 month |
|---|---|---|
| 2026-06-30 | 456.15K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-06 | 1.65M shares derived: sum of 4 quarters · filed 2026-08-06 |
| 2026-03-31 | 536.72K shares 10-Q · filed 2026-05-07 | 1.20M shares derived: sum of 4 quarters · filed 2026-05-07 |
| 2025-12-31 | 73.17K shares derived: 10-K 12 month − 10-Q 9 month · filed 2026-02-26 | 773.88K shares 10-K · filed 2026-02-26 |
| 2025-09-30 | 586.91K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-06 | 924.90K shares derived: sum of 4 quarters · filed 2025-11-06 |
| 2025-06-30 | 0.00 shares derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-11 | 629.17K shares derived: sum of 4 quarters · filed 2025-08-11 |
| 2025-03-31 | 113.79K shares 10-Q · filed 2025-05-06 | 952.17K shares derived: sum of 4 quarters · filed 2025-05-06 |
| 2024-12-31 | 224.20K shares derived: 10-K 12 month − 10-Q 9 month · filed 2025-02-27 | 968.59K shares 10-K · filed 2025-02-27 |
| 2024-09-30 | 291.18K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2024-11-06 | 864.94K shares derived: sum of 4 quarters · filed 2024-11-06 |
| 2024-06-30 | 322.99K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-01 | 796.44K shares derived: sum of 4 quarters · filed 2024-08-01 |
| 2024-03-31 | 130.21K shares 10-Q · filed 2024-05-07 | 842.14K shares derived: sum of 4 quarters · filed 2024-05-07 |
| 2023-12-31 | 120.55K shares derived: 10-K 12 month − 10-Q 9 month · filed 2024-02-28 | 916.24K shares 10-K · filed 2024-02-28 |
| 2023-09-30 | 222.69K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-07 | 905.77K shares derived: sum of 4 quarters · filed 2023-11-07 |
| 2023-06-30 | 368.69K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-08 | 1.01M shares derived: sum of 4 quarters · filed 2023-08-08 |
| 2023-03-31 | 204.31K shares 10-Q · filed 2023-05-08 | 773.79K shares derived: sum of 4 quarters · filed 2023-05-08 |
| 2022-12-31 | 110.09K shares derived: 10-K 12 month − 10-Q 9 month · filed 2023-02-27 | 720.90K shares 10-K · filed 2023-02-27 |
| 2022-09-30 | 331.64K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-03 | 800.73K shares derived: sum of 4 quarters · filed 2022-11-03 |
| 2022-06-30 | 127.75K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2022-08-08 | 697.14K shares derived: sum of 4 quarters · filed 2022-08-08 |
| 2022-03-31 | 151.42K shares 10-Q · filed 2022-05-05 | 837.91K shares derived: sum of 4 quarters · filed 2022-05-05 |
| 2021-12-31 | 189.92K shares derived: 10-K 12 month − 10-Q 9 month · filed 2022-02-28 | 1.02M shares 10-K · filed 2022-02-28 |
| 2021-09-30 | 228.05K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2021-11-04 | 1.44M shares derived: sum of 4 quarters · filed 2021-11-04 |
| 2021-06-30 | 268.52K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2021-08-04 | 1.63M shares derived: sum of 4 quarters · filed 2021-08-04 |
| 2021-03-31 | 334.63K shares 10-Q · filed 2021-05-05 | 1.56M shares derived: sum of 4 quarters · filed 2021-05-05 |
| 2020-12-31 | 613.07K shares derived: 10-K 12 month − 10-Q 9 month · filed 2021-02-26 | 1.49M shares 10-K · filed 2021-02-26 |
| 2020-09-30 | 412.39K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-05 | 961.76K shares derived: sum of 4 quarters · filed 2020-11-05 |
| 2020-06-30 | 202.40K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-07 | 783.33K shares derived: sum of 4 quarters · filed 2020-08-07 |
| 2020-03-31 | 259.57K shares 10-Q · filed 2020-05-07 | 846.70K shares derived: sum of 4 quarters · filed 2020-05-07 |
| 2019-12-31 | 87.40K shares derived: 10-K 12 month − 10-Q 9 month · filed 2020-02-27 | 786.64K shares 10-K · filed 2020-02-27 |
| 2019-09-30 | 233.96K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2019-11-06 | 860.23K shares derived: sum of 4 quarters · filed 2019-11-06 |
| 2019-06-30 | 265.78K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2019-08-06 | 824.20K shares derived: sum of 4 quarters · filed 2019-08-06 |
| 2019-03-31 | 199.50K shares 10-Q · filed 2019-05-08 | 768.24K shares derived: sum of 4 quarters · filed 2019-05-08 |
| 2018-12-31 | 160.99K shares derived: 10-K 12 month − 10-Q 9 month · filed 2019-03-12 | 650.47K shares 10-K · filed 2019-03-12 |
| 2018-09-30 | 197.93K shares derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-08 | |
| 2018-06-30 | 209.82K shares derived: 10-Q 6 month − 10-Q 3 month · filed 2018-08-09 | |
| 2018-03-31 | 81.73K shares 10-Q · filed 2018-05-11 | |
| 2017-12-31 | 695.19K shares 10-K · filed 2019-03-12 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Tarsus Pharmaceuticals, Inc. (TARS) | United States | $3.329B | -58.60 |
| Relay Therapeutics, Inc. (RLAY) | United States | $3.884B | -14.30 |
| Beam Therapeutics Inc. (BEAM) | United States | $2.549B | -41.51 |
| Greenland Mines Ltd (GRML) | United States | $2.362B | |
| BIOCRYST PHARMACEUTICALS INC (BCRX) | United States | $2.175B | -6.63 |
| ADMA BIOLOGICS, INC. (ADMA) | United States | $2.131B | 11.16 |
| Kodiak Sciences Inc. (KOD) | United States | $2.090B | -10.12 |
| RECURSION PHARMACEUTICALS, INC. (RXRX) | United States | $2.080B | -3.78 |
| Vericel Corp (VCEL) | United States | $2.011B | 93.97 |
| Adaptive Biotechnologies Corp (ADPT) | United States | $4.719B | -53.43 |